查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046463

肺炎鏈球菌疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、適應症、產品、分銷、地區和競爭格局分類，2021-2031年

Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Product, By Distribution, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺炎鏈球菌疫苗市場預計將從 2025 年的 97.1 億美元大幅成長至 2031 年的 139.8 億美元，複合年成長率為 6.26%。

該市場主要由用於對抗肺炎球菌（肺炎鏈球菌）的結合疫苗和多醣疫苗組成。推動市場成長的主要因素包括肺炎鏈球菌感染的增加、各國免疫接種計劃的擴大以及易患呼吸道感染疾病的老年人口的成長，所有這些因素都增加了各國對預防措施的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 97.1億美元
市場規模：2031年 139.8億美元
複合年成長率：2026-2031年 6.26%
成長最快的細分市場 結合疫苗
最大的市場 北美洲

然而，高昂的生產和採購成本仍然是一大挑戰，限制了發展中地區獲得疫苗的機會，並阻礙了免疫規劃的全面實施。儘管世界衛生組織（世衛組織）2024年的數據顯示，已有163個成員國引進了疫苗，全球整體第三劑接種率達到67%，但這些差距凸顯了在確保公平供應和資金支持永續市場擴張方面仍然存在的困難。

市場促進因素

推動全球肺炎鏈球菌疫苗市場發展的兩大主要因素是政府主導的國家免疫規劃的擴展，尤其是在疫苗取得管道有限的中低收入國家，這是重要的驅動力。與地方政府的國際夥伴關係正在擴大疫苗引進的財政負擔分擔，從而促進永續採購。這種成本分擔模式不僅確保了生產者的穩定需求，也有助於將肺炎鏈球菌結合疫苗納入常規免疫計畫。全球疫苗免疫聯盟（Gavi）在其2024年度進度報告中指出，2024年各國為Gavi支持的疫苗提供的共同融資達到創紀錄的2.55億美元，顯示各國對免疫接種的財政投入顯著增加。

其次，老年人口的不斷成長，尤其是老年人，更容易肺炎鏈球菌感染，這推動了全球對高效預防性疫苗的需求。隨著老齡化成長，免疫力下降，老年人嚴重侵襲性肺炎鏈球菌感染的風險更高，因此，重點關注成人疫苗接種至關重要。根據環境科學研究所2024年的報告，侵襲性肺炎鏈球菌感染（IPD）的發生率在65歲及以上人口中最高，為每10萬人34.2例。輝瑞等製藥巨頭正抓住這一需求，在其2025年第三季財報中，總銷售額達到167億美元，這主要得益於其沛（Prevnar）疫苗系列的強勁表現。

市場挑戰

肺炎鏈球菌疫苗市場成長的最大障礙是疫苗生產和採購成本高昂，尤其是中低收入國家。結合疫苗的生產涉及複雜的生物過程，需要大量資金投入，這推高了疫苗價格，並加重了各國醫療預算的負擔。這種財政壓力往往迫使開發中國家難以在國內籌集資金，只好依賴外部援助來進行免疫計畫。當政府面臨預算限制時，會導致疫苗採購延遲和部署受限，直接阻礙這些關鍵地區疫苗接種率和市場規模的成長。

這種財政負擔可以透過開發中國家沉重的經濟負擔來量化。根據全球疫苗免疫聯盟（Gavi）的報告，低收入國家將在2024年透過共同資金籌措為其免疫規劃貢獻約2.55億美元，比前一年成長19%。這種不斷成長的財政負擔凸顯了資源匱乏國家在維持廣泛免疫接種率方面持續面臨的困難，並表明如果沒有持續的外部財政支持，疫苗市場的全面擴張將受到限制。

市場趨勢

肺炎鏈球菌疫苗市場正經歷一場重大變革，其主要特徵體現在兩大趨勢上。首先，向超多價結合疫苗的轉型正在加速，生產商的目標是提供比目前20價疫苗更廣泛的血清型覆蓋。這一轉變旨在應對“替代現象”，即由於疫苗未覆蓋的血清型而導致的疾病爆發，並推動了下一代肺炎球菌結合疫苗（PCV）的快速研發和商業化，尤其是在成人疫苗方面。這些覆蓋範圍更廣的疫苗獲得了市場的廣泛認可。例如，默克公司新推出的21價疫苗Capvaxive，由於市場需求強勁，預計在2025年第三季銷售額將達到2.44億美元。這凸顯了擴大疫苗價在降低侵襲性肺炎鏈球菌感染的臨床重要性。

其次，開發中地區低成本、在地化疫苗生產的興起正在改變西方跨國公司主導的傳統權力結構。特別是印度生物技術公司，正在迅速擴大生產以滿足全球南方（南半球發展中國家）的需求，從而減少對外國援助的依賴，並緩解國際採購延誤。這項策略擴張得到了基礎設施和研發領域大量投資的支持，以確保自給自足的穩定供應。例如，Biological E. Limited公司已投資400億盧比建立了一座最先進的疫苗生產設施。這表明，此類投資在為全球提供價格合理的肺炎球菌疫苗以及確保中低收入國家公平獲得疫苗方面發揮著至關重要的作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肺炎鏈球菌疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（結合疫苗、多醣體疫苗）
    • 適應症（支氣管炎、腦膜炎、肺炎、敗血症）
    • 依產品（Pneumovax23、Prevnar 13、Synflorix）
    • 通路（政府機構、非政府組織）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肺炎鏈球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肺炎鏈球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肺炎鏈球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肺炎鏈球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肺炎鏈球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肺炎鏈球菌疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GSK PLC
  • Pfizer Inc
  • Merck KGaA
  • Serum Institute of India Pvt Ltd
  • CSL Ltd
  • Sanofi SA
  • Walvax Biotechnology Co., Ltd
  • Beijing Minhai Biotechnology Limited Company
  • AstraZeneca PLC
  • BioNTech

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18803

The global pneumococcal vaccine market is projected to expand significantly, from USD 9.71 billion in 2025 to USD 13.98 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.26%. This market primarily consists of conjugate and polysaccharide vaccines developed to combat Streptococcus pneumoniae. Growth is largely propelled by an increase in pneumococcal diseases, the expansion of national immunization initiatives, and a growing elderly population prone to respiratory infections, driving demand for preventative solutions across all economies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.71 Billion
Market Size 2031USD 13.98 Billion
CAGR 2026-20316.26%
Fastest Growing SegmentConjugate Vaccines
Largest MarketNorth America

However, high manufacturing and procurement costs pose a substantial challenge, restricting access in developing regions and impeding the complete rollout of immunization programs. Data from the World Health Organization in 2024 indicates that while 163 Member States had introduced the vaccine, achieving 67% global third-dose coverage, these disparities underscore ongoing difficulties in ensuring fair supply and funding for sustained market expansion.

Market Driver

Two primary factors are fueling the global pneumococcal vaccine market. First, the expansion of government-led national immunization programs, especially in low- and middle-income countries where access has been limited, is a major driver. International partnerships with local governments are increasingly sharing the financial load of vaccine implementation, fostering sustainable procurement. This cost-sharing model not only ensures consistent demand for manufacturers but also promotes the inclusion of pneumococcal conjugate vaccines in routine schedules. Gavi, the Vaccine Alliance, reported in its 2024 Annual Progress Report that country co-financing for Gavi-supported vaccines hit a record US$255 million in 2024, indicating a significant rise in domestic financial commitment to immunization.

Second, the increasing geriatric population, highly susceptible to pneumococcal infections, is boosting demand for advanced prophylactic vaccines globally. As immunity weakens with age, the elderly are at a higher risk of severe invasive pneumococcal disease, necessitating focused adult vaccination efforts. Data from the Institute of Environmental Science and Research's 2024 report showed that adults aged 65 and above had the highest incidence of IPD at 34.2 per 100,000. Pharmaceutical giants like Pfizer capitalize on this demand; their Third-Quarter 2025 Results reported total revenues of $16.7 billion, partly driven by the strong performance of their Prevnar vaccine family.

Market Challenge

The most significant obstacle to the pneumococcal vaccine market's growth, particularly in lower and middle-income countries, is the elevated cost of vaccine manufacturing and procurement. The intricate biological processes involved in producing conjugate vaccines demand substantial capital, leading to high prices that burden national health budgets. This financial pressure often forces developing nations to depend on external aid for immunization programs, as they struggle to self-finance procurement. When governments face budget limitations, it results in delayed purchases or restricted rollout, directly hindering vaccine uptake and market volume growth in these crucial regions.

This financial strain is quantifiable through the increasing monetary obligations placed on developing economies. Gavi, the Vaccine Alliance, reported that in 2024, lower-income countries contributed nearly US$255 million to their own vaccination programs through co-financing, a 19% increase from the prior year. This rising financial strain highlights the ongoing difficulty for resource-limited nations to maintain widespread immunization coverage, thereby constraining the market's full expansion without continuous external financial support.

Market Trends

The pneumococcal vaccine market is undergoing significant transformation, marked by two key trends. Firstly, there's an accelerated move towards ultra-high valency conjugate vaccines, with manufacturers striving to offer broader serotype coverage beyond current 20-valent options. This shift aims to counter the "replacement phenomenon," where non-vaccine serotypes cause disease, leading to rapid development and commercialization of next-generation PCVs, particularly for adults. The market has shown strong acceptance of these broader-spectrum vaccines, as exemplified by Merck & Co., Inc.'s newly launched 21-valent vaccine, Capvaxive, which generated US$244 million in sales in Q3 2025 due to robust demand. This highlights the clinical importance of expanded valency in reducing invasive pneumococcal disease.

Secondly, the rise of cost-effective indigenous vaccine manufacturing in developing regions is disrupting the traditional dominance of Western multinational companies. Local biotechnology firms, especially in India, are rapidly increasing production to meet demand in the Global South, thus reducing dependency on external aid and mitigating international procurement delays. This strategic expansion is backed by significant investments in infrastructure and research to ensure independent supply security. For instance, Biological E. Limited committed ₹4,000 crore to establish advanced vaccine facilities, demonstrating the crucial role of such investments in providing affordable pneumococcal vaccines globally and ensuring fair access in low- and middle-income countries.

Key Market Players

  • GSK PLC
  • Pfizer Inc
  • Merck KGaA
  • Serum Institute of India Pvt Ltd
  • CSL Ltd
  • Sanofi SA
  • Walvax Biotechnology Co., Ltd
  • Beijing Minhai Biotechnology Limited Company
  • AstraZeneca PLC
  • BioNTech

Report Scope

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumococcal Vaccine Market, By Type

  • Conjugate Vaccines
  • Polysaccharide Vaccines

Pneumococcal Vaccine Market, By Indication

  • Bronchitis
  • Meningitis
  • Pneumonia
  • Sepsis

Pneumococcal Vaccine Market, By Product

  • Pneumovax23
  • Prevnar 13
  • Synflorix

Pneumococcal Vaccine Market, By Distribution

  • Government Authorities
  • Non-Governmental Organizations

Pneumococcal Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.

Available Customizations:

Global Pneumococcal Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumococcal Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Conjugate Vaccines, Polysaccharide Vaccines)
    • 5.2.2. By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis)
    • 5.2.3. By Product (Pneumovax23, Prevnar 13, Synflorix)
    • 5.2.4. By Distribution (Government Authorities, Non-Governmental Organizations)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Pneumococcal Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Product
    • 6.2.4. By Distribution
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pneumococcal Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By Distribution
    • 6.3.2. Canada Pneumococcal Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By Distribution
    • 6.3.3. Mexico Pneumococcal Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By Distribution

7. Europe Pneumococcal Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Product
    • 7.2.4. By Distribution
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pneumococcal Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By Distribution
    • 7.3.2. France Pneumococcal Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By Distribution
    • 7.3.3. United Kingdom Pneumococcal Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By Distribution
    • 7.3.4. Italy Pneumococcal Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By Distribution
    • 7.3.5. Spain Pneumococcal Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By Distribution

8. Asia Pacific Pneumococcal Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Product
    • 8.2.4. By Distribution
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pneumococcal Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By Distribution
    • 8.3.2. India Pneumococcal Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By Distribution
    • 8.3.3. Japan Pneumococcal Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By Distribution
    • 8.3.4. South Korea Pneumococcal Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Product
        • 8.3.4.2.4. By Distribution
    • 8.3.5. Australia Pneumococcal Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Product
        • 8.3.5.2.4. By Distribution

9. Middle East & Africa Pneumococcal Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Product
    • 9.2.4. By Distribution
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pneumococcal Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By Distribution
    • 9.3.2. UAE Pneumococcal Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By Distribution
    • 9.3.3. South Africa Pneumococcal Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By Distribution

10. South America Pneumococcal Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Indication
    • 10.2.3. By Product
    • 10.2.4. By Distribution
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pneumococcal Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By Distribution
    • 10.3.2. Colombia Pneumococcal Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By Distribution
    • 10.3.3. Argentina Pneumococcal Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By Distribution

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pneumococcal Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GSK PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc
  • 15.3. Merck KGaA
  • 15.4. Serum Institute of India Pvt Ltd
  • 15.5. CSL Ltd
  • 15.6. Sanofi SA
  • 15.7. Walvax Biotechnology Co., Ltd
  • 15.8. Beijing Minhai Biotechnology Limited Company
  • 15.9. AstraZeneca PLC
  • 15.10. BioNTech

16. Strategic Recommendations

17. About Us & Disclaimer